Connection

Yuki Kageyama to Cell Line, Tumor

This is a "connection" page, showing publications Yuki Kageyama has written about Cell Line, Tumor.
Connection Strength

0.270
  1. STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-?-induced Apoptosis in Urothelial Cancer. Anticancer Res. 2024 May; 44(5):1925-1930.
    View in: PubMed
    Score: 0.139
  2. Suppression of mutant androgen receptors by flutamide. Int J Urol. 2009 May; 16(5):516-21.
    View in: PubMed
    Score: 0.049
  3. Leu-574 of human HIF-1alpha is a molecular determinant of prolyl hydroxylation. FASEB J. 2004 Jun; 18(9):1028-30.
    View in: PubMed
    Score: 0.035
  4. Development of a novel interferon-a2b gene construct with a repetitive hypoxia-inducible factor binding site and its suppressive effects on human renal cell carcinoma cell lines in vitro. Int J Clin Oncol. 2014; 19(3):497-504.
    View in: PubMed
    Score: 0.016
  5. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer. Prostate. 2008 Oct 01; 68(14):1570-81.
    View in: PubMed
    Score: 0.012
  6. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 1):6012-7.
    View in: PubMed
    Score: 0.010
  7. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells. Am J Physiol Endocrinol Metab. 2004 Jun; 286(6):E927-31.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.